BioAge
Drug Discovery & Development
BioAge is a clinical-stage biopharmaceutical company developing therapeutic candidates for metabolic diseases by targeting the biology of human aging.
About BioAge
BioAge Labs researches molecular pathways that contribute to aging with an AI-driven platform to extend the human healthspan.
Mission & Approach
Mission
“We are harnessing the biology of human aging to develop new therapies for metabolic diseases”
AI Approach
predictive analytics
Products & Solutions
BioAge Discovery Platform
platformHuman-first multi-omics platform for identifying molecular mediators of aging
A proprietary discovery platform that analyzes multi-omics data captured over decades to identify molecular mediators of aging and disease. The platform enables identification of key pathways that drive metabolic aging, forming the basis for BioAge's pipeline programs targeting metabolic diseases.
APJ Agonist Program
otherExercise mimetic targeting apelin receptor for obesity treatment
An apelin receptor (APJ) agonist designed as an exercise mimetic for obesity. Preclinical models show potential to double weight loss and fully restore body composition when combined with incretins. The program targets a molecule secreted in response to exercise. IND submission is anticipated by 2026 year end.
BGE-102
FlagshipotherNovel oral NLRP3 inhibitor for cardiovascular risk and metabolic dysfunction
BGE-102 is BioAge's lead program targeting NLRP3, an anti-inflammatory pathway linked to cardiovascular risk and metabolic dysfunction. The oral inhibitor has demonstrated potential best-in-class reductions in hsCRP in Phase 1 trials. Full Phase 1 data is anticipated in the first half of 2026.
Customer Success Stories
Phase 1 Clinical Trial Participants
other
Evaluation of BGE-102 for reducing inflammation markers in patients at cardiovascular risk
Hiring Activity
View Open Roles →Product & Market
Product Stage
growthPrimary Market
pharmaCompany Details
- Founded
- 2015
- Headquarters
- Richmond, CA, USA
- Employees
- 100
- Stage
- public
- Profile last updated
- June 22, 2026
Category
Drug Discovery & DevelopmentWork here?
Claim this listing to update company information and connect with our audience.
Claim This ListingData Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as employee counts and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.